Page 2 - Jon Chen News Today

/PRNewswire/ -- Collide Capital, one of the largest Black-owned first time funds, is supporting intersectional founders solving the next generation of global...

/PRNewswire/ -- Collide Capital, one of the largest Black-owned first time funds, is supporting intersectional founders solving the next generation of global...

A movement to divest from fossil fuel is gaining support among foundations as activists...

A movement to divest from fossil fuel is gaining support among foundations as activists...

A movement to divest from fossil fuel is gaining support among foundations as activists...

/PRNewswire/ -- IsoPlexis, the leader in functional single-cell proteomics, today announced the acquisition of an extensive intellectual property portfolio of...

Published: May 18, 2021 IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe. BRANFORD, Conn., May 18, 2021 /PRNewswire/ -- IsoPlexis, the leader in single-cell proteomics, today announced an exclusive agreement with Bucher Biotec AG, a Swiss distributor company representing some of the most advanced US, European, and Asian manufacturers of highly innovative lif...

Share this article Share this article BRANFORD, Conn., May 13, 2021 /PRNewswire/ -- IsoPlexis, the leader in single-cell proteomics, today announced that Jason Ou has joined the company as General Manager for the Asia-Pacific (APAC) region. In this role, Mr. Ou will continue to advance IsoPlexis growth and expand the companys customer base in the APAC region. "We are pleased to have Jason join our leadership team at IsoPlexis," said Peter Siesel, Chief Commercial Officer of IsoPlexis. "Jas...

IsoPlexis Appoints Siddhartha Kadia to its Board of Directors News provided by Share this article Share this article BRANFORD, Conn., May 11, 2021 /PRNewswire/ -- IsoPlexis, the leader in functional single-cell proteomics, today announced the appointment of Siddhartha Kadia to its Board of Directors. Dr. Kadia joins IsoPlexis Board of Directors with over 20 years of experience in evolving a combination of technology, life science and healthcare industries. Dr. Siddhartha Kadia previously serve...

IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors Posted Jan 08, 2021 BRANFORD, Conn., Jan. 8, 2021 /BiopharmaDive/ -- IsoPlexis, the leader in single-cell functional proteomics, announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility. The round was led by Perceptive Advisors with participation from other new investors, Ally Bridge Group and funds and accounts managed by BlackRock, as w...